Key result
Hypertension is linked to elevated MMP-9 and hypertensive ESRD to elevated MMP-2 and MMP-10.
Why the study?
The contribution of matrix metalloproteinase enzymes as inflammatory mediators to hypertension and its target organ consequences required investigation.
Are plasma levels of matrix metalloproteinases elevated in patients with uncomplicated hypertension and hypertensive end-stage renal disease compared to normotensive controls?
Observational
Are plasma levels of matrix metalloproteinases elevated in patients with uncomplicated hypertension and hypertensive end-stage renal disease compared to normotensive controls?
Discrete patterns of MMP overexpression exist in hypertension, with MMP-9 elevated early and MMP-2 and MMP-10 linked to target organ damage such as ESRD.
MMP elevations may mark hypertensive progression to ESRD; leaves open their value as biomarkers or targets pending longitudinal validation.
The contribution of inflammation to hypertension and target organ damage is under investigation. The matrix metalloproteinase (MMP) enzymes are inflammatory mediators that may contribute to hypertension and its target organ consequences. Here we probe MMPs as inflammatory mediators in hypertension, by studying all three MMP classes in uncomplicated hypertension as well hypertension with profound renal damage, such as hypertensive end-stage renal disease (ESRD). We assayed plasma levels of five MMPs: one collagenase (MMP-1), two gelatinases (MMP-2, MMP-9), and two stromelysins (MMP-3, MMP-10). In hypertension, MMP-9 was elevated versus normotensive controls. Systolic blood pressure (SBP) in all three subject groups positively correlated with MMP-9. In hypertensive-ESRD, MMP-2 and MMP-10 were elevated compared to both hypertensive and normotensive subjects. Several correlations occurred across MMPs, suggesting coordinate biosynthetic control. Our results suggest discrete patterns of MMP overexpression in hypertension, with MMP-9 elevated early, and MMP-2 and MMP-10 linked to target organ damage.
No takes yet. Share an insight, caveat, or question.
Friese et al. (2009) conducted an observational in Essential Hypertension and Hypertensive End-Stage Renal Disease. Hypertension and hypertensive ESRD vs. Normotensive controls was evaluated on Plasma levels of MMP-1, MMP-2, MMP-3, MMP-9, and MMP-10. Hypertension was associated with elevated MMP-9, while hypertensive end-stage renal disease was associated with elevated MMP-2 and MMP-10 compared to normotensive controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: